Craig T, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2012;5(12):182–99.
Article
PubMed
PubMed Central
Google Scholar
Bowen T, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary Angioedema. J Allergy Clin Immunol. 2004;114(3):629–37.
Article
PubMed
Google Scholar
Gompels MM, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379–94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bowen T, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 international consensus algorithm for the diagnosis, therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30–40.
Article
CAS
PubMed
Google Scholar
Bowen T, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
Article
PubMed
PubMed Central
Google Scholar
Longhurst HJ, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):22.
Article
PubMed
PubMed Central
Google Scholar
Caballero T, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21(5):333–47. quiz follow 347
CAS
PubMed
Google Scholar
Caballero T, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011;21(6):422–41. quiz 442-3
CAS
PubMed
Google Scholar
Caballero T, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129(2):308–20.
Article
PubMed
Google Scholar
Cicardi M, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group. Allergy. 2012;67(2):147–57.
Article
CAS
PubMed
Google Scholar
Lang DM, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012;109(6):395–402.
Article
PubMed
Google Scholar
Wahn V, et al. Hereditary angioedema (HAE) in children and adolescents-a consensus on therapeutic strategies. Eur J Pediatr. 2012;171:1339-48.
Cicardi M, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary Angioedema international working group. Allergy. 2014;69(5):602–16.
Article
CAS
PubMed
Google Scholar
Longhurst HJ, et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol. 2015;180(3):475–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Farkas H, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017;72(2):300–13.
Article
CAS
PubMed
Google Scholar
Reshef A, Kidon M, Leibovich I. The story of Angioedema: from Quincke to Bradykinin. Clin Rev Allergy Immunol. 2016;51(2):121–39.
Article
PubMed
Google Scholar
Brozek JL, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669–77.
Article
CAS
PubMed
Google Scholar
Guyatt GH, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400.
Article
PubMed
Google Scholar
Brozek JL, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588–95.
Article
CAS
PubMed
Google Scholar
Black N, et al. Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy. 1999;4(4):236–48.
Article
CAS
PubMed
Google Scholar
Bork K, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–74.
Article
PubMed
Google Scholar
Cicardi M, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982;284(1):2–9.
Article
CAS
PubMed
Google Scholar
Dinkelacker E. Ueber acutes Oedem. In: Medicinische Facultät zu Kiel. Kiel: Liel; 1882. p. 27.
Google Scholar
Rosen FS, Austen KF. The “neurotic edema” (hereditary angioedema). N Engl J Med. 1969;280(24):1356–7.
Article
CAS
PubMed
Google Scholar
Zuraw BL, Christiansen SC. HAE Pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216–29.
Article
CAS
PubMed
Google Scholar
Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53(3):373–88. quiz 389-92
Article
PubMed
Google Scholar
Hedner T, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992;304(6832):941–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nussberger J, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351(9117):1693–7.
Article
CAS
PubMed
Google Scholar
Donaldson VH, Evans RR. A biochemical abnormality in Herediatry Angioneurotic edema: absence of serum inhibitor of C’ 1-esterase. Am J Med. 1963;35:37–44.
Article
CAS
PubMed
Google Scholar
Rosen FS, et al. Hereditary Angioneurotic edema: two genetic variants. Science. 1965;148(3672):957–8.
Article
CAS
PubMed
Google Scholar
Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286–9.
Article
CAS
PubMed
Google Scholar
Bafunno V, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2017. In press.
Bork K, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018;73(2):442-50.
Caldwell JR, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39–52.
Article
Google Scholar
Schreiber AD, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976;48(4):567–80.
CAS
PubMed
Google Scholar
Zanichelli A, et al. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. J Allergy Clin Immunol Pract. 2017;5(5):1307-13.
Zuberbier T, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87.
Article
CAS
PubMed
Google Scholar
Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153–8.
Article
CAS
PubMed
Google Scholar
Zanichelli A, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.
Article
PubMed
PubMed Central
Google Scholar
Germenis AE, Speletas M. Genetics of hereditary Angioedema revisited. Clin Rev Allergy Immunol. 2016;51(2):170–82.
Article
CAS
PubMed
Google Scholar
Lopez-Lera A, et al. SERPING1 mutations in 59 families with hereditary angioedema. Mol Immunol. 2011;49(1–2):18–27.
Article
CAS
PubMed
Google Scholar
Pappalardo E, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106(6):1147–54.
Article
CAS
PubMed
Google Scholar
Donaldson VH, Rosen FS. Action of complement in hereditary Angioneurotic edema: the role of C’1-esterase. J Clin Invest. 1964;43:2204–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kaplan AP, Joseph K. Complement, Kinins, and hereditary Angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol. 2016;51(2):207–15.
Article
CAS
PubMed
Google Scholar
Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109(2):195–209.
Article
CAS
PubMed
Google Scholar
Donaldson VH. Kinin formation in hereditary angioneurotic edema (HANE) plasma. Int Arch Allergy Appl Immunol. 1973;45(1):206–9.
Article
CAS
PubMed
Google Scholar
Whalley ET, Amure YO, Lye RH. Analysis of the mechanism of action of bradykinin on human basilar artery in vitro. Naunyn Schmiedeberg's Arch Pharmacol. 1987;335(4):433–7.
Article
CAS
Google Scholar
Whalley ET, et al. Analysis of the receptors mediating vascular actions of bradykinin. Naunyn Schmiedeberg's Arch Pharmacol. 1987;336(4):430–3.
Article
CAS
Google Scholar
Jacques L, et al. Capillary permeability induced by intravenous neurokinins. Receptor characterization and mechanism of action. Naunyn Schmiedeberg's Arch Pharmacol. 1989;340(2):170–9.
Article
CAS
Google Scholar
Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol. 1983;72(1):54–60.
Article
CAS
PubMed
Google Scholar
Maurer M, et al. New topics in bradykinin research. Allergy. 2011;66(11):1397–406.
Article
CAS
PubMed
Google Scholar
Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106(3):546–50.
Article
CAS
PubMed
Google Scholar
Bork K, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213–7.
Article
CAS
PubMed
Google Scholar
de Maat S, et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol. 2016;138(5):1414–23. e9
Article
CAS
PubMed
Google Scholar
Zuraw BL, Christiansen SC. Pathogenesis and laboratory diagnosis of hereditary angioedema. Allergy Asthma Proc. 2009;30(5):487–92.
Article
CAS
PubMed
Google Scholar
Aabom A, Bygum A, Koch C. Complement factor C4 activation in patients with hereditary angioedema. Clin Biochem. 2017;50(15):816-21.
Karim Y, Griffiths H, Deacock S. Normal complement C4 values do not exclude hereditary angioedema. J Clin Pathol. 2004;57(2):213–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tarzi MD, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol. 2007;149(3):513–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pedrosa M, et al. Complement study versus CINH gene testing for the diagnosis of type I hereditary Angioedema in children. J Clin Immunol. 2016;36(1):16–8.
Article
PubMed
Google Scholar
Ebo DG, et al. Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. J Allergy Clin Immunol Pract. 2018;6(1):277-79.
Betschel S, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10(1):50.
Article
PubMed
PubMed Central
Google Scholar
Rasmussen ER, de Freitas PV, Bygum A. Urticaria and Prodromal symptoms including Erythema Marginatum in Danish patients with hereditary Angioedema. Acta Derm Venereol. 2016;96(3):373–6.
Article
CAS
PubMed
Google Scholar
Staubach P, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–44.
Article
CAS
PubMed
Google Scholar
Bernstein JA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–7.
Article
PubMed
Google Scholar
Peveling-Oberhag A, et al. High-concentration liquid Prednisolone formula: filling a therapeutic niche in severe acute attacks of Urticaria and Angioedema. Skin Pharmacol Physiol. 2016;29(1):9–12.
Article
CAS
PubMed
Google Scholar
Bork K, et al. Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy. 2017;72(2):320–4.
Article
CAS
PubMed
Google Scholar
Bouillet L, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol. 2009;103(5):448.
Article
PubMed
Google Scholar
Cronin JA, Maples KM. Treatment of an acute attack of type III hereditary angioedema with ecallantide. Ann Allergy Asthma Immunol. 2012;108(1):61–2.
Article
PubMed
Google Scholar
Bouillet L, et al. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert(R)) in a French cohort. Eur J Dermatol. 2017;27(2):155–9.
PubMed
Google Scholar
Magerl M, et al. Hereditary Angioedema with normal C1 inhibitor: update on evaluation and treatment. Immunol Allergy Clin N Am. 2017;37(3):571–84.
Article
Google Scholar
Toh S, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172(20):1582–9.
Article
CAS
PubMed
Google Scholar
Magerl M, et al. Bradykinin in health and disease: proceedings of the Bradykinin symposium 2012, Berlin 23-24 august 2012. Inflamm Res. 2014;63(3):173–8.
Article
CAS
PubMed
Google Scholar
Bas M, Hoffmann TK, Kojda G. Icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(19):1867–8.
PubMed
Google Scholar
Bas M, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372(5):418–25.
Article
PubMed
CAS
Google Scholar
Straka BT, et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol. 2017;140(1):242-48.
Gobert D, et al. A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients. Medicine (Baltimore). 2016;95(33):e4363.
Article
CAS
PubMed Central
Google Scholar
Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin N Am. 2006;26(4):709–24.
Article
Google Scholar
Farkas H, et al. “Nuts and bolts” of laboratory evaluation of Angioedema. Clin Rev Allergy Immunol. 2016;51(2):140–51.
Article
CAS
PubMed
Google Scholar
Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc. 2006;81(7):958–72.
Article
CAS
PubMed
Google Scholar
Bork K, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229–35.
Article
PubMed
Google Scholar
Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–7.
Article
PubMed
Google Scholar
Lumry WR, et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529–37.
Article
CAS
PubMed
Google Scholar
Riedl MA, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163–9. e1
Article
CAS
PubMed
Google Scholar
Cicardi M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cicardi M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523–31.
Article
CAS
PubMed
Google Scholar
Zuraw BL, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–22.
Article
CAS
PubMed
Google Scholar
Craig TJ, et al. C1 esterase inhibitor concentrate in 1085 hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study. Allergy. 2011;66(12):1604–11.
Article
CAS
PubMed
Google Scholar
Craig TJ, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801–8.
Article
CAS
PubMed
Google Scholar
Craig TJ, et al. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;111(3):211–5.
Article
CAS
PubMed
Google Scholar
Maurer M, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773.
Article
CAS
PubMed
PubMed Central
Google Scholar
Banta E, Horn P, Craig TJ. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc. 2011;32(4):319–24.
Article
CAS
PubMed
Google Scholar
de Rojas Hernandez Fernandez D, et al. Treatment of HAE attacks in the Icatibant outcome survey: an analysis of Icatibant self-administration versus administration by health care professionals. Int Arch Allergy Immunol. 2015;167(1):21–8.
Article
CAS
Google Scholar
Aygoren-Pursun E, et al. On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol. 2010;6(1):21.
Article
PubMed
PubMed Central
Google Scholar
Cicardi M, et al. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol. 2013;161(Suppl 1):3–9.
Article
PubMed
Google Scholar
Muhlberg H, Ettl N, Magerl M. An analysis of the teaching of intravenous self-administration in patients with hereditary angio-oedema. Clin Exp Dermatol. 2016;41(4):366–71.
Article
CAS
PubMed
Google Scholar
Zanichelli A, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy. 2011;66(2):192–6.
Article
CAS
PubMed
Google Scholar
Craig TJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010;30(6):823–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kunschak M, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38(6):540–9.
Article
CAS
PubMed
Google Scholar
Schulz KH. Hereditary Quincke's edema. New therapeutic ways. Hautarzt. 1974;25(1):12–6.
CAS
PubMed
Google Scholar
Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334(25):1630–4.
Article
CAS
PubMed
Google Scholar
Brackertz D, Isler E, Kueppers F. Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy. 1975;5(1):89–94.
Article
CAS
PubMed
Google Scholar
Martinez-Saguer I, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010;50(2):354–60.
Article
CAS
PubMed
Google Scholar
Martinez-Saguer I, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54(6):1552–61.
Article
CAS
PubMed
Google Scholar
Hofstra JJ, et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor(R)): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol. 2012;142(3):280–90.
Article
CAS
PubMed
Google Scholar
Bernstein JA, et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010;105(2):149–54.
Article
CAS
PubMed
Google Scholar
Terpstra FG, et al. Viral safety of C1-inhibitor NF. Biologicals. 2007;35(3):173–81.
Article
CAS
PubMed
Google Scholar
De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com. Transfus Apher Sci. 2003;29(3):247–54.
Article
PubMed
Google Scholar
Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion. 2012;52(10):2104-12.
van Doorn MB, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116(4):876–83.
Article
CAS
PubMed
Google Scholar
van Veen HA, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol. 2012;162(2–3):319–26.
Article
CAS
PubMed
Google Scholar
Farrell C, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol. 2013;76(6):897–907.
Article
CAS
PubMed
PubMed Central
Google Scholar
PharmingGroup. Ruconest prescribing information. 2014; Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf.
Google Scholar
Riedl M. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. Clin Drug Investig. 2015;35(7):407–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moldovan D, Bernstein JA, Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy. 2015;7(7):739–52.
Article
CAS
PubMed
Google Scholar
Moldovan D, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy. 2012;42(6):929–35.
Article
CAS
PubMed
Google Scholar
Shire. Kalbitor prescribing information. 2015; Available from: http://www.shirecontent.com/PI/PDFs/Kalbitor_USA_ENG.pdf. [21 Aug 2017].
Google Scholar
DyaxCorp., Withdrawal of Kalbitor at EMA. 2011.
Google Scholar
Craig TJ, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(2):206–12. e4
Article
PubMed
Google Scholar
Levy RJ, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523–9.
Article
CAS
PubMed
Google Scholar
Sheffer AL, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol. 2011;128(1):153–9. e4
Article
CAS
PubMed
Google Scholar
Rocha ESM, Beraldo WT, Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Phys. 1949;156(2):261–73.
Google Scholar
Antonio A, Rocha ESM. Coronary vasodilation produced by bradykinin on isolated mammalian heart. Circ Res. 1962;11:910–5.
Article
CAS
PubMed
Google Scholar
Erikson U. Peripheral Arteriography during Bradykinin induced Vasodilation. Acta Radiol Diagn (Stockh). 1965;3:193–201.
Article
CAS
Google Scholar
Bork K, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007;119(6):1497–503.
Article
CAS
PubMed
Google Scholar
Farkas H. Icatibant as acute treatment for hereditary angioedema in adults. Expert Rev Clin Pharmacol. 2016;9(6):779–88.
Article
CAS
PubMed
Google Scholar
Bork K, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58–64.
Article
PubMed
Google Scholar
Farkas H, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor--a long-term survey. Allergy. 2012;67(12):1586–93.
CAS
PubMed
Google Scholar
Nanda MK, et al. A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. Ann Allergy Asthma Immunol. 2014;113(2):198–203.
Article
PubMed
PubMed Central
Google Scholar
Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc. 2003;134(8):1088–94.
Article
PubMed
Google Scholar
Forrest A, Milne N, Soon A. Hereditary angioedema: death after a dental extraction. Aust Dent J. 2017;62(1):107–10.
Article
CAS
PubMed
Google Scholar
Frank MM. Hereditary angioedema: short-term prophylaxis for surgery. Allergy Asthma Proc. 2012;33(4):303–4.
Article
PubMed
Google Scholar
Aygoren-Pursun E, et al. Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history. Allergy. 2013;68(8):1034–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jurado-Palomo J, et al. Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2013;23(1):1–6.
CAS
PubMed
Google Scholar
Farkas H, et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg. 1999;57(4):404–8.
Article
CAS
PubMed
Google Scholar
Magerl M, et al. Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: findings from an international patient registry. Ann Allergy Asthma Immunol. 2017;118(1):110–2.
Article
CAS
PubMed
Google Scholar
Shire. Cinryze prescribing information. 2017; Available from: https://www.shire.de/-/media/shire/shireglobal/shiregermany/pdffiles/product%20information/fi-cinryze.pdf.
Google Scholar
Behring, C. Berinert 500/1500 prescribing information. 2017; Available from: http://www.berinert.de/documents/64158/69464/FI_Berinert_April_2016.pdf/a5ed7d04-0c28-4f5a-994d-896a1e8031cd. Accessed 1 Feb 2018.
Frank MM. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin N Am. 2013;33(4):495–503.
Article
Google Scholar
Greve J, et al. Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. J Dtsch Dermatol Ges. 2016;14(3):266–75.
PubMed
Google Scholar
Maurer M, Magerl M. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J Dtsch Dermatol Ges. 2011;9(2):99–107.
PubMed
Google Scholar
Bernstein JA, et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2014;2(1):77–84.
Article
PubMed
Google Scholar
Longhurst H, et al. Prevention of hereditary Angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–40.
Article
CAS
PubMed
Google Scholar
Lumry WR, et al. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc. 2014;35(5):371–6.
Article
CAS
PubMed
Google Scholar
Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125(9):938. e1-7
Article
PubMed
CAS
Google Scholar
Craig T, et al. Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema. Allergy Rhinol (Providence). 2017;8(1):13–9.
Article
Google Scholar
Riedl MA, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017;30;390(10102):1595-602.
Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc. 2013;34(6):519–22.
Article
PubMed
Google Scholar
Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014;35(6):444–53.
Article
CAS
PubMed
Google Scholar
Riedl MA, et al. Safety and usage of C1-inhibitor in hereditary Angioedema: Berinert registry data. J Allergy Clin Immunol Pract. 2016;4(5):963–71.
Article
PubMed
Google Scholar
Ärzteschaft Add. Schwerwiegende Thrombenbildung nach Berinert® HS. Deutsches Ärzteblatt. 2000;97:A-1016.
Google Scholar
Farkas H, et al. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc. 2016;37(2):164–70.
Article
PubMed
Google Scholar
Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med. 2009;122(8):780–3.
Article
PubMed
Google Scholar
Blackmore WP. Danazol in the treatment of hereditary angio-neurotic oedema. J Int Med Res. 1977;5(Suppl 3):38–43.
PubMed
Google Scholar
Agostoni A, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol. 1980;65(1):75–9.
Article
CAS
PubMed
Google Scholar
Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol. 2002;36(5):707–9.
Article
PubMed
Google Scholar
Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153–61.
Article
CAS
PubMed
Google Scholar
Farkas H, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol. 2010;66(4):419–26.
Article
CAS
PubMed
Google Scholar
Fust G, et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Investig. 2011;41(3):256–62.
Article
CAS
Google Scholar
Thoufeeq MH, Ishtiaq J, Abuzakouk M. Danazol-induced Hepatocellular carcinoma in a patient with hereditary Angioedema. J Gastrointest Cancer. 2012;43(Suppl 1):S280–2.
Article
PubMed
Google Scholar
Berkel AE, et al. Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema. Neth J Med. 2014;72(7):380–2.
CAS
PubMed
Google Scholar
Rahal S, et al. Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema. Case Rep Oncol. 2014;7(3):825–7.
Article
PubMed
PubMed Central
Google Scholar
Kohalmi KV, et al. The effect of long-term danazol treatment on haematological parameters in hereditary angioedema. Orphanet J Rare Dis. 2016;11:18.
Article
PubMed
PubMed Central
Google Scholar
Zuraw BL, et al. Tolerability and effectiveness of 17-alpha-Alkylated androgen therapy for hereditary Angioedema: a re-examination. J Allergy Clin Immunol Pract. 2016;4(5):948–55. e15
Article
PubMed
Google Scholar
Zotter Z, et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet J Rare Dis. 2014;9:205.
Article
PubMed
PubMed Central
Google Scholar
Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol. 1992;99(3):212–5.
Article
CAS
PubMed
Google Scholar
Wentz AC. Adverse effects of danazol in pregnancy. Ann Intern Med. 1982;96(5):672–3.
Article
CAS
PubMed
Google Scholar
Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003;24(4):523–38.
Article
CAS
PubMed
Google Scholar
Wu YS, et al. Intracranial hypertension associated with danazol withdrawal: a case report. Acta Neurol Taiwanica. 2007;16(3):173–6.
Google Scholar
Farkas H, et al. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol. 2002;13(3):153–61.
Article
PubMed
Google Scholar
Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287(9):452–4.
Article
CAS
PubMed
Google Scholar
Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand. 1972;192(4):293–8.
CAS
PubMed
Google Scholar
Bonnekoh H, et al. Hereditary Angioedema due to C1-INH deficiency: age of onset and delay in diagnosis in Germany. Warsaw: Dpt. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin: Global Forum on Hereditary Angioedema; 2016.
Google Scholar
Bork K, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349–54.
Article
CAS
PubMed
Google Scholar
Martinez-Saguer I, et al. Does early clinical manifestation of hereditary Angioedema (HAE) influence the clinical course of the disease? J Allergy Clin Immunol. 2013;131(2):AB30.
Article
Google Scholar
Christiansen SC, et al. Pediatric hereditary Angioedema: onset, diagnostic delay, and disease severity. Clin Pediatr (Phila). 2016;55(10):935–42.
Article
Google Scholar
Boyle RJ, Nikpour M, Tang ML. Hereditary angio-oedema in children: a management guideline. Pediatr Allergy Immunol. 2005;16(4):288–94.
Article
PubMed
Google Scholar
Caballero T. Angio-oedema due to hereditary C1 inhibitor deficiency in children. Allergol Immunopathol (Madr). 2013;41(1):45–53.
Article
CAS
Google Scholar
Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol. 2010;6(1):18.
Article
PubMed
PubMed Central
Google Scholar
Martinez-Saguer I, Farkas H. Erythema Marginatum as an early symptom of hereditary Angioedema: case report of 2 newborns. Pediatrics. 2016;137(2):e20152411.
Article
PubMed
Google Scholar
Frank MM, et al. Management of Children with Hereditary Angioedema due to C1 inhibitor deficiency. Pediatrics. 2016;138(5).
Grumach AS, et al. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79(4):276–81.
Article
CAS
PubMed
Google Scholar
Nielsen EW, et al. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35(2):184–7.
Article
CAS
PubMed
Google Scholar
Aabom A, et al. Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema. Orphanet J Rare Dis. 2017;12(1):55.
Article
PubMed
PubMed Central
Google Scholar
Spath PJ, Wuthrich B. Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms. Recenti Prog Med. 1990;81(7–8):513–31.
CAS
PubMed
Google Scholar
Pappalardo E, et al. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol. 2008;45(13):3536–44.
Article
CAS
PubMed
Google Scholar
Speletas M, et al. Hereditary angioedema: molecular and clinical differences among European populations. J Allergy Clin Immunol. 2015;135(2):570–3.
Article
PubMed
Google Scholar
Pharming. Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary Angioedema, from 2 up to and including 13 years of age. 2017; Available from: https://clinicaltrials.gov/ct2/show/NCT01359969.
Shire. A multicenter, open-label, non-randomized study to assess the pharmacokinetics, tolerability, and safety of a single subcutaneous Administration of Icatibant in children and adolescents with hereditary Angioedema. 2017; Available from: https://clinicaltrials.gov/ct2/show/NCT01386658.
Google Scholar
Kreuz W, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion. 2012;52(1):100–7.
Article
CAS
PubMed
Google Scholar
Lumry W, et al. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema. Pediatr Allergy Immunol. 2015;26(7):674–80.
Article
PubMed
Google Scholar
Bowen T. Hereditary angioedema consensus 2010. Allergy Asthma Clin Immunol. 2010;6(1):13.
Article
PubMed
PubMed Central
Google Scholar
Farkas H, et al. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol. 2013;131(2):579–82. e1-2
Article
PubMed
Google Scholar
Zotter Z, et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2014;9:44.
Article
PubMed
PubMed Central
Google Scholar
Bouillet L, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol. 2008;199(5):484. e1-4
Article
PubMed
Google Scholar
Saule C, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013;43(4):475–82.
Article
CAS
PubMed
Google Scholar
Czaller I, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44–9.
Article
CAS
PubMed
Google Scholar
Martinez-Saguer I, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol. 2010;203(2):131. e1-7
Article
PubMed
CAS
Google Scholar
Gonzalez-Quevedo T, et al. Management of Pregnancy and Delivery in patients with hereditary Angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol. 2016;26(3):161–7.
Article
CAS
PubMed
Google Scholar
Caballero T, et al. Management of hereditary angioedema in pregnant women: a review. Int J Womens Health. 2014;6:839–48.
Article
PubMed
PubMed Central
Google Scholar
Halbmayer WM, et al. C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost. 1991;65(2):134–8.
CAS
PubMed
Google Scholar
Ogston D, Walker J, Campbell DM. C1 inactivator level in pregnancy. Thromb Res. 1981;23(4–5):453–5.
Article
CAS
PubMed
Google Scholar
Fox J, et al. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. Allergy Asthma Proc. 2017;38(3):216–21.
Article
PubMed
Google Scholar
Farkas H, et al. First report of icatibant treatment in a pregnant patient with hereditary angioedema. J Obstet Gynaecol Res. 2016;42(8):1026–8.
Article
PubMed
Google Scholar
Fernando SL, Li J. Hereditary cause of severe recurrent bowel swelling that requires targeted therapy. Med J Aust. 2014;200(3):179.
Article
PubMed
Google Scholar
Zanichelli A, Mansi M, Periti G. Icatibant exposure during pregnancy in a patient with hereditary Angioedema. J Investig Allergol Clin Immunol. 2015;25(6):447–9.
CAS
PubMed
Google Scholar
Galan HL, et al. Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. J Reprod Med. 1996;41(7):541–4.
CAS
PubMed
Google Scholar
Nathani F, Sullivan H, Churchill D. Pregnancy and C1 esterase inhibitor deficiency: a successful outcome. Arch Gynecol Obstet. 2006;274(6):381–4.
Article
PubMed
Google Scholar
Caliskaner Z, et al. A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema. Allergol Immunopathol (Madr). 2007;35(3):117–9.
Article
CAS
Google Scholar
Farkas H, et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol. 2012;165(2):366–7.
Article
PubMed
Google Scholar
Gorman PJ. Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. Can Fam Physician. 2008;54(3):365–6.
PubMed
PubMed Central
Google Scholar
Bouillet L, et al. Hereditary angioedema treatments: recommendations from the French national center for angioedema (Bordeaux consensus 2014). Presse Med. 2015;44(5):526–32.
Article
PubMed
Google Scholar
Gilad O, et al. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med. 2014;9(8):407–10.
Article
PubMed
Google Scholar
Banerji A, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc. 2015;36(3):213–7.
Article
PubMed
PubMed Central
Google Scholar
Boccon-Gibod I. Hereditary angioedema: treatment and educational therapeutic program. Presse Med. 2015;44(1):78–88.
Article
PubMed
Google Scholar
Nasr IH, et al. Optimizing hereditary angioedema management through tailored treatment approaches. Expert Rev Clin Immunol. 2016;12(1):19–31.
Article
CAS
PubMed
Google Scholar
Banerji A, et al. Expert perspectives on hereditary angioedema: key areas for advancements in care across the patient journey. Allergy Rhinol (Providence). 2016;7(3):172–81.
Article
Google Scholar
Bernstein JA, et al. Facilitating home-based treatment of hereditary angioedema. Allergy Asthma Proc. 2015;36(2):92–9.
Article
CAS
PubMed
Google Scholar
Bygum A. Hereditary angioedema - consequences of a new treatment paradigm in Denmark. Acta Derm Venereol. 2014;94(4):436–41.
Article
CAS
PubMed
Google Scholar
Li HH. Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance. Patient Prefer Adherence. 2016;10:1727–37.
Article
PubMed
PubMed Central
Google Scholar
Tourangeau LM, et al. Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol. 2012;157(4):417–24.
Article
CAS
PubMed
Google Scholar
Tuong LA, Olivieri K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. Allergy Asthma Proc. 2014;35(3):250–4.
Article
PubMed
Google Scholar
Wilson DA, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(4):314–20.
Article
PubMed
Google Scholar
Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511–9.
Article
PubMed
Google Scholar
Abdel-Karim O, Dizdarevic A, Bygum A. Hereditary angioedema: children should be considered for training in self-administration. Pediatr Dermatol. 2014;31(6):e132–5.
Article
PubMed
Google Scholar
Visy B, et al. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter. 2007;12(3):251–7.
Article
PubMed
Google Scholar
Caballero T, et al. Triggers and Prodromal symptoms of Angioedema attacks in patients with hereditary Angioedema. J Investig Allergol Clin Immunol. 2016;26(6):383–6.
Article
CAS
PubMed
Google Scholar
Zotter Z, et al. Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1-inhibitor deficiency. Allergy. 2016;71(12):1791–3.
Article
CAS
PubMed
Google Scholar
Riedl MA. Creating a comprehensive treatment plan for hereditary angioedema. Immunol Allergy Clin N Am. 2013;33(4):471–85.
Article
Google Scholar
Zuraw BL, et al. US hereditary Angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–67.
Article
PubMed
Google Scholar